Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model

BACKGROUND: Currently, there is no cure for Alzheimer’s disease (AD). Therapeutics that can modify the early stage of AD are urgently needed. Recent studies have shown that the pathogenesis of AD is closely regulated by an endo/lysosomal asparaginyl endopeptidase (AEP). Inhibition of AEP has been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ju, Hu, Hui-Jie, Liu, Zi-Kai, Liu, Jing-Jing, Wang, Shan-Shan, Cheng, Qing, Chen, Hong-Zhuan, Song, Mingke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015189/
https://www.ncbi.nlm.nih.gov/pubmed/33789744
http://dx.doi.org/10.1186/s40035-021-00235-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015189/
https://www.ncbi.nlm.nih.gov/pubmed/33789744
http://dx.doi.org/10.1186/s40035-021-00235-4

Ejemplares similares